Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Patients With Advanced Unresectable Melanoma
NCT05539118Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human interferon alpha-1b, toripalimab and anlotinib in melanoma, sponsored by Xijing Hospital. Primary endpoints: Recommended Phase II Dose at 12 weeks, Objective Response Rate up to 24 months and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
recombinant human interferon alpha-1btoripalimabanlotinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05539118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539118.